Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Seres Therapeutics, Inc. (MCRB) had Stock-Based Compensation of $5.16M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-19.86M |
|
-- |
|
-- |
|
$24.88M |
|
$-24.88M |
|
$5.03M |
|
$-19.86M |
|
$-19.86M |
|
$-19.86M |
|
$-19.86M |
|
$-19.86M |
|
$-19.86M |
|
$-24.88M |
|
$-23.82M |
|
8.74M |
|
8.74M |
|
$-2.27 |
|
$-2.27 |
|
| Balance Sheet Financials | |
$48.69M |
|
$9.62M |
|
$95.11M |
|
$143.80M |
|
$30.94M |
|
-- |
|
$79.91M |
|
$110.85M |
|
$32.95M |
|
$32.95M |
|
$32.95M |
|
8.75M |
|
| Cash Flow Statement Financials | |
$13.62M |
|
$-0.21M |
|
$1.18M |
|
$39.46M |
|
$54.05M |
|
$14.59M |
|
|
Stock-Based Compensation |
$5.16M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.57 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$13.41M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-60.26% |
|
-60.26% |
|
-13.81% |
|
-60.26% |
|
$3.76 |
|
$1.53 |
|
$1.56 |
|